Aehr Test Systems stock hits 52-week high at $46.97

AEHR hit a 52-week high ($46.97) and is trading at $47.70 with a $1.39B market cap after a ~527% one‑year surge (InvestingPro reports a 510% one‑year return). The company won an initial order from a major data‑center optical transceiver customer for multiple wafer‑level burn‑in systems (shipping in fiscal Q4 ending May 29, 2026) and received a follow‑on production order from its lead silicon photonics customer including a FOX‑XP and ultra‑high power upgrade; William Blair reiterated an Outperform. InvestingPro flags the stock as overvalued per its Fair Value analysis, tempering the bullish operational developments.

Analysis

Aehr sits at the intersection of an early-stage secular ramp (silicon photonics and AI optical I/O) and a classic capital-equipment-to-aftermarket revenue transition. The near-term narrative will be driven by the cadence of production shipments and WaferPak consumable adoption; each FOX-XP deployed can create a multi-year consumables revenue stream that meaningfully boosts gross margins if utilization rates reach mid-60%+, but that outcome requires both program wins and timely equipment deliveries.

Second-order winners include WaferPak/contact carrier suppliers, precision aligner vendors, and OSATs that will see higher test content per die; legacy electrical-only tester vendors and low-cost contract manufacturers risk losing share as photonics shifts testing earlier to wafer-level processes. Expect pressure on lead times and pricing for FOX-XP assemblies if Aehr cannot ramp supply quickly—backlogs could either re-rate growth expectations upward (if demand is genuine) or translate to elongated revenue recognition and margin compression.

Key risks are concentrated-customer exposure, execution on scaling complex capital equipment manufacturing, and valuation compression if AI capex re-prioritizes away from optical I/O. Watchable catalysts over the next 3–12 months: (1) confirmation of production revenue conversion and recurring consumables attach rates, (2) order backlog / delivery cadence disclosures, and (3) any competing wafer-level test announcements from larger incumbents — any miss on these points is likely to trigger rapid multiple contraction in a richly priced name.

Key Decisions for Investors

• Long AEHR via defined-cost options (6–12 month call spread): buy AEHR 9–12 month 55–80 call spread sized for 1–3% portfolio exposure. Rationale: limited premium outlay to capture a successful production ramp; target 50–100% upside on the spread if shipments and attach rates meet expectations, max loss = premium (~100%).
• Long AEHR equity with tactical hedge: purchase AEHR stock (2–4% portfolio) and short SMCI equal-dollar (1–2% portfolio) to isolate photonics test share gains vs broad AI server cyclicality. Rationale: hedges macro AI capex drawdown while keeping exposure to company-specific wins; set a 20% trailing stop on the AEHR leg and tighten hedge if SMCI outperforms by >15% in 30 days.
• Event-driven short / protective put: buy 3-month AEHR put (or small short) if upcoming quarter shows delayed shipment or weak consumable guidance. Rationale: high valuation leaves downside asymmetric—a single missed production conversion can drive 30–50% downside in weeks.
• Monitor and scale on confirmation: if Aehr reports multi-quarter recurring consumable attach rates >20% of trailing equipment revenue and book-to-bill >1.2, scale long positions to 5% of portfolio within 6–12 months. Risk/reward: target 2x price from current levels over 12 months, but re-assess if gross margin expansion lags.